News

Fintel reports that on August 11, 2023, HC Wainwright & Co. reiterated coverage of Akebia Therapeutics (NASDAQ:AKBA) with a Neutral recommendation.

Analyst Price Forecast Suggests 108.16% Upside

As of August 2, 2023, the average one-year price target for Akebia Therapeutics is 3.06. The forecasts range from a low of 2.02 to a high of $4.20. The average price target represents an increase of 108.16% from its latest reported closing price of 1.47.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Akebia Therapeutics is 203MM, a decrease of 24.96%. The projected annual non-GAAP EPS is -0.46.

What is the Fund Sentiment?

There are 105 funds or institutions reporting positions in Akebia Therapeutics. This is a decrease of 20 owner(s) or 16.00% in the last quarter. Average portfolio weight of all funds dedicated to AKBA is 0.11%, an increase of 37.00%. Total shares owned by institutions increased in the last three months by 1.33% to 54,871K shares.

The put/call ratio of AKBA is 0.07, indicating a bullish outlook.

What are Other Shareholders Doing?

Satter Management Co. holds 16,205K shares representing 8.72% ownership of the company. In it's prior filing, the firm reported owning 15,090K shares, representing an increase of 6.88%. The firm increased its portfolio allocation in AKBA by 19.81% over the last quarter.

Acadian Asset Management holds 7,460K shares representing 4.01% ownership of the company. In it's prior filing, the firm reported owning 7,483K shares, representing a decrease of 0.30%. The firm increased its portfolio allocation in AKBA by 52.61% over the last quarter.

VEXPX - VANGUARD EXPLORER FUND Investor Shares holds 4,698K shares representing 2.53% ownership of the company. No change in the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,967K shares representing 2.13% ownership of the company. In it's prior filing, the firm reported owning 2,411K shares, representing an increase of 39.23%. The firm increased its portfolio allocation in AKBA by 47.58% over the last quarter.

Renaissance Technologies holds 3,331K shares representing 1.79% ownership of the company. In it's prior filing, the firm reported owning 2,338K shares, representing an increase of 29.79%. The firm increased its portfolio allocation in AKBA by 116.45% over the last quarter.

Akebia Therapeutics Background Information
(This description is provided by the company.)

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Additional reading:

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.